Sanofi Entered into a Research Collaboration with Insilico Medicine for ~$1.2B
Shots:
- Insilico Medicine to receive ~$21.5M up front and target nomination fees for ~6 targets & is also eligible to receive ~$1.2B upon achievement of research, development, and sales milestones along with royalties
- In return, Sanofi gets the benefit from Insilico’s end-to-end Pharma.AI platform & will receive access to the company’s scientific team to identify, synthesize, and advance high-quality lead therapeutic compounds up to development candidate stage
- The collaboration helps to advance the development candidates for ~6 new targets by using Insilico Medicine’s AI platform, Pharma.AI & Sanofi’s strong drug research, and development expertise
Ref: Globenewswire | Image: Sanofi
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
